Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin

Inclusion Criteria: * Informed consent obtained before any trial-related activities * Any subjects at onset of Type 1 Diabetes * Treatment with either Insulin Aspart and Soluble Human Insulin or Soluble Human Insulin and Isophane Human Insulin / Mixtard® for at least 9 months from the time of diagnosis of diabetes Exclusion Criteria: * Treatment with immunosuppressive agents * For the Insulin Aspart + Isophane Human Insulin: Treatment with insulin analogues other than Insulin Aspart or treatment with fast acting human insulin for a period of 7 days or more during the treatment period * For the Soluble Human Insulin and Isophane Human Insulin group: Treatment with insulin analogues * Other diseases influencing immune response * Unable or unwilling to provide consent